Write in a clean editor, then format for Alzheimer s & Dementia Translational Research & Clinical Interventions in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Alzheimer s & Dementia Translational Research & Clinical Interventions is a peer-reviewed journal published by Elsevier, covering Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Geriatric Care and Nursing Homes.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Alzheimer s & Dementia Translational Research & Clinical Interventions 12 (2023) 45–58.
Formats any DOI in Alzheimer s & Dementia Translational Research & Clinical Interventions style. No sign-up. |
| Publishes research in | Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Geriatric Care and Nursing Homes Functional Brain Connectivity Studies Cholinesterase and Neurodegenerative Diseases |
| ISSN | 2352-8737 |
| Citation impact (2-yr) | 4.23 |
| h-index | 85 |
| i10-index | 591 |
| Total citations | 35,031 |
| Article processing charge | $2,200 |
| Open access | Yes |
| Top institutions publishing here | University of California, San Francisco |
| Journal website | www.trci.alzdem.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the…
INTRODUCTION: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices. METHODS: We reviewed clinicaltrials.gov and identified all pharmacologic AD trials of…
INTRODUCTION: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov. METHODS: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented…
This article provides a brief overview of the processes of drug discovery and development. Our aim is to help scientists whose research may be relevant to drug discovery and/or development to frame their research report in a way that appropriately places their findings within the drug discovery and development process and thereby support effective translation…
Introduction: Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods: We searched the governmental website clinicaltrials.gov where are all clinical trials…
